Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. QQQ
8. LDOS
9. HUM
10. KTOS

Go back to Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer

Bristol-Myers Squibb Co. (BMY) PT Lowered to $47 at BMO Capital; See Much Uncertainty and Increased Risk

January 23, 2017 1:46 PM EST

BMO Capital analyst Alex Arfaei lowered his price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $47.00 (from $53.00) while maintaining a Market Perform rating. The firm still sees much uncertainty and Increased execution risk and thinks a takeout/merger is less likely.

Arfaei commented,... More

Cowen Downgrades Bristol-Myers Squibb Co. (BMY) to Market Perform

January 20, 2017 7:44 AM EST

Cowen downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $55.49 yesterday.

... More